The Association Between Body Composition and Biomarkers in Hemodialysis Patients
试验速览
- 阶段
- 4 期
- 入组人数
- 160
- 试验地点
- 2
- 主要终点
- blood pressure
研究概览
简要总结
Control of volume status is a pivotal issue in haemodialysis therapy. Objective and practical management for maintaining normovolemia is needed.
The investigators hypothesized that intervention of volume status with the body composition monitor (BCM) may improved hemodynamic parameters and biomarkers in hemodialysis patients.
详细描述
The investigators will assess BCM in enrolled hemodialysis patients by 4 weeks for 16 weeks During the former 8-week intervention period, The investigators will adjust patients' volume status according to the results of BCM.
During the latter 8-week observational period, The investigators will evaluate the changes of patients' hemodynamic parameters and biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •6-month or more stable hemodialysis patients
- •18 years or more
- •less than 5% of changes of dry weight for last 3 months
排除标准
- •pregnancy
- •active malignancy
- •cardiac pacemaker or defibrillator
- •history of extremity amputation
- •active infectious disease within 3 months
- •admission history for complication related to hemodialysis within 3 months
结局指标
主要结局
blood pressure
时间窗: up to 16 weeks
Systolic blood pressure, number of anti-hypertensive agents hypotensive episode
次要结局
- biomarkers(up to 16 weeks)